Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. is reported to have 3,592,740 shares of its common stock beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin in a joint filing. This position represents 3.25% of the company’s common stock, based on 110,427,682 shares outstanding as of May 8, 2026. All 3,592,740 shares are held with shared voting and dispositive power and no sole power, with ownership information stated as of June 30, 2026.

Key Figures

Beneficially owned shares: 3,592,740 shares Percent of class: 3.25% Shares outstanding baseline: 110,427,682 shares +2 more

5 metrics

Beneficially owned shares 3,592,740 shares Common stock beneficially owned by the reporting persons as of June 30, 2026

Percent of class 3.25% Percentage of Viridian Therapeutics common stock beneficially owned

Shares outstanding baseline 110,427,682 shares Shares outstanding as of May 8, 2026, used to calculate ownership percentages

Shared voting power 3,592,740 shares Shares over which the reporting persons share voting power

Shared dispositive power 3,592,740 shares Shares over which the reporting persons share dispositive power

Key Terms

beneficially owned, shared voting power, shared dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 3,592,740"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared power to vote or to direct the vote: 3,592,740"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared power to dispose or to direct the disposition of: 3,592,740"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

Joint Filing Statement regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

What ownership stake in VRDN is reported by Deep Track Capital in this Schedule 13G/A?

Deep Track Capital and related reporting persons report beneficial ownership of 3,592,740 shares of Viridian Therapeutics (VRDN) common stock, representing 3.25% of the outstanding shares based on 110,427,682 shares outstanding.

How is voting power over Viridian Therapeutics (VRDN) shares allocated for the reporting persons?

The reporting persons have 0 shares with sole voting power and 3,592,740 shares with shared voting power. They also have shared dispositive power over the same 3,592,740 shares and no sole dispositive power.

Who are the reporting persons in this Viridian Therapeutics (VRDN) Schedule 13G/A amendment?

The reporting persons are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. Deep Track Capital is cited as the relevant entity for which David Kroin may be considered a control person.

What share count did the VRDN ownership percentages use as the basis?

The beneficial ownership percentages are calculated using 110,427,682 shares of Viridian Therapeutics common stock outstanding, as reported by the issuer in a prospectus filed on May 8, 2026.

As of what date is the Deep Track ownership in Viridian Therapeutics (VRDN) reported?

The reporting persons state that their ownership information in Viridian Therapeutics common stock is as of June 30, 2026, incorporating share totals and percentages derived from the issuer’s earlier outstanding share figure.

Does this Viridian Therapeutics (VRDN) filing indicate ownership above or below 5% of the class?

The filing states beneficial ownership of 3.25% of the class, and explicitly references that the reporting persons hold 5 percent or less of Viridian Therapeutics’ outstanding common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 08:33 AM Accepted by SEC EDGAR 08/14/2026 - 08:32 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

VIRIDIAN THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,592,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,592,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,592,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.25 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,592,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,592,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,592,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.25 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,592,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,592,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,592,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.25 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VIRIDIAN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 221 Crescent Street, Suite 103A, Waltham, MA 02453
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, $0.01 par value
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,592,740
(b)	Percent of class: 3.25%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,592,740
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,592,740
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	08/14/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	08/14/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	08/14/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of June 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 110,427,682 shares outstanding as of May 8, 2026, as reported by the issuer on its Prospectus filed with the SEC on May 8, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin